Evecxia Therapeutics Reports Favorable Data From a Phase 1 SAD/MAD Trial
Quotient Sciences has supported Evecxia with the Phase 1 two-part single ascending dose (SAD) and multiple ascending dose (MAD) trial of EVX-101 in healthy volunteers treated with escitalopram. Favorable safety, tolerability, pharmacokinetic, and pharmacodynamic data was announced from the study.